Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $222.67M.
ENTERPRISE VALUE (EV)
$222.67M
Anika Therapeutics, Inc.
Market Cap
$255.95M
Enterprise Value (EV)
$222.67M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Anika Therapeutics, Inc. (ANIK) | $255.95M | $222.67M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $257.94M | $171.92M |
| AC Immune S.A. (ACIU)vs › | $258.00M | $228.73M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $258.80M | $208.32M |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $260.79M | $142.92M |
| Palisade Bio, Inc. (PALI)vs › | $262.11M | $136.93M |
| OraSure Technologies, Inc. (OSUR)vs › | $262.66M | $114.17M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $262.79M | $231.58M |
| Upstream Bio, Inc. (UPB)vs › | $248.43M | $169.98M |
| Quantum-Si incorporated (QSI)vs › | $248.27M | $227.87M |
Market Cap
$255.95M
Total Debt
$24.20M
Cash
$57.48M
Enterprise Value
$222.67M
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Why use EV instead of Market Cap?
